$128 million contract win: Are Pro Medicus shares a strong buy?

Resumen detallado
I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic. The post $128 million contract win: Are Pro Medicus shares…
Pro Medicus Ltd (ASX: PME) shares are rising on Friday following another major contract announcement.
The medical imaging technology company has secured a $128 million agreement in the United States, adding to its growing list of customer wins.
But does this latest deal make Pro Medicus shares a strong buy? Here's how I see things.
This morning, Pro Medicus announced that it has signed a 10-year, $128 million contract with NYC Health + Hospitals.
This is a significant customer win. NYC Health + Hospitals is the largest municipal healthcare system in the United States, serving more than 1 million patients annually across more than 70 locations.
Under the agreement, Pro Medicus will provide its complete Visage 7 enterprise imaging platform, including its Viewer, Workflow, and Open Archive products.
The software will be deployed through the cloud, with operations expected to commence in the third quarter of calendar year 2027.
Importantly, the agreement is based on a transaction-based licensing model, with potential upside beyond the announced contract value.
This means Pro Medicus could generate additional revenue if imaging volumes exceed expectations.
Inicio del artículo, extracto de The Motley Fool Australia. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com.au)




